Expert Comparison
Both are proven GLP-1 medications for weight loss. Here's how they compare — mechanism, results, side effects, and pricing.
Side-by-side
Mechanism, clinical results, dosing, and REMEVi pricing — at a glance.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 agonist |
| Avg Weight Loss | 14.9% body weight | 22.5% body weight |
| Clinical Trial | STEP 1 (68 weeks) | SURMOUNT-1 (72 weeks) |
| Brand Names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Dosing | 0.25mg → 2.0mg weekly | 2.5mg → 15mg weekly |
| REMEVi Price | $149 first month, then $279/mo | $249 first month, then $379/mo |
| Best For | Steady, proven results | Maximum weight loss |
Semaglutide mimics the GLP-1 hormone, reducing appetite and slowing gastric emptying. Clinical trials showed an average 14.9% body weight loss over 68 weeks.
Starts at 0.25mg weekly, gradually increasing to 2.0mg over 16-20 weeks.
One flat price at every dose. Most weight-loss programs raise your price every time your dose goes up — REMEVi never does. Visit, medication, coaching and shipping — one number. No separate membership fee. (Many programs add a $79–$149/mo membership on top of the medication price.)
Provider-managed weekly injection. The same compounded GLP-1 as the big-brand competitors — with bilingual care, no insurance, no dose upcharges.
Daily oral semaglutide. Same clinical oversight, same bilingual care — without the needle.
Dual-agonist tirzepatide. The strongest average loss in the GLP-1 category — provider-managed, bilingual care.
¹ Clinical-trial results for semaglutide (STEP-1, NEJM 2021) and tirzepatide (SURMOUNT-1, NEJM 2022) — the active medications in REMEVi protocols, not REMEVi outcomes or guarantees. Compounded preparations are not FDA-approved and have not been studied as finished products. Individual results vary.
FAQ
Tirzepatide (22.5% avg) showed greater weight loss than semaglutide (14.9% avg) in clinical trials. However, individual results vary and your licensed provider will help determine the best option for you.
Yes, your REMEVi licensed provider can help you transition between medications if needed. Some patients start with semaglutide and move to tirzepatide for enhanced results.
Both medications share similar GI side effects (nausea, constipation). Tirzepatide may have slightly higher rates initially due to dual mechanism, but most side effects are mild and temporary.
Tirzepatide is a newer, dual-mechanism medication with stronger clinical results. The higher cost reflects the more complex compounding process and stronger clinical profile.
Yes, both medications require a prescription from a licensed provider. REMEVi includes clinical review in your monthly price — no separate consultation fee.
Take the free 1-minute quiz for a personalized recommendation — if you qualify, a secure 5-minute medical intake follows.
Free · no card required
